(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2001 (28.06.2001)

PCT

(10) International Publication Number
WO 01/45705 A1

(51) International Patent Classification[7]: A61K 31/415, 9/20, A61P 19/02, A61K 31/42

(21) International Application Number: PCT/US00/34752

(22) International Filing Date:
20 December 2000 (20.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/171,738	22 December 1999 (22.12.1999)	US
60/181,635	10 February 2000 (10.02.2000)	US
60/202,269	5 May 2000 (05.05.2000)	US

(71) Applicant *(for all designated States except US)*: **PHARMACIA CORPORATION** [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HEDDEN, David, B.** [US/US]; 1012 South Delphia Avenue, Park Ridge, IL 60068 (US). **NADKARNI, Sreekant** [IN/US]; 6957 Morgan Court, Gurnee, IL 60031 (US).


(74) Agents: **FORBES, James, C.** et al.; Pharmacia Corporation, Corporate Law Dept., P.O. Box 5110, Chicago, IL 60680 (US).

(81) Designated States *(national)*: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: SUSTAINED-RELEASE FORMULATION OF A CYCLOOXYGENASE-2 INHIBITOR



(57) Abstract: There is provided an orally deliverable pharmaceutical composition comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility such as celecoxib and a release-extending polymer. The composition is useful in treatment of cyclooxygenase-2 mediated conditions and disorders by once-a-day administration.

WO 01/45705 A1

IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *With international search report.*

— *Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.